Popular Searches
Strategic cooperation with Lotus Lake BioMedical Technology

TAILIN Medical Engineering (wholly-owned subsidiary of TAILIN ) and LotusLake BioMedical Technology (cell and gene therapy innovation center) jointly develop the project of "sterile transport system & biological decontamination workstation" aiming to build the first clean logistics GMP factory in the world by using automatic clean logistics system. For this strategic agreement, TAILIN Medical Engineering & LotusLake BioMedical Technology mainly focus on the technological innovation of cell and gene therapy equipments, and carries out cooperation in clean logistics and transportation to seek new development in the field of biomedicine.


LotusLake BioMedical Technology is a technology company co-founded by Tsinghua Industrial Research Institute and some industry leaders in China that is responsible for the construction and operation of the Cell and Gene Therapy Innovation Center. It is oriented to the R & D of innovative drugs for cell & gene therapy, and cooperates with top international scientific research institutions to apply synthetic biotechnology to the field of bioengineering and integrate technologies such as artificial intelligence, intelligent robots and 5G industrial Internet.

For us, relying on years of accumulation of aseptic isolation & biological contamination control technology and through the R&D breakthrough of several integrated key technologies, TAILIN Medical Engineering comprehensively lays out the upstream industry chain of new biopharmaceuticals, provides key production equipment for cutting-edge therapeutic technologies such as cell and gene drugs, and builds a full ecological chain from technology development to application validation. Focusing on preclinical research, clinical research and drug registration of innovative cell and gene therapy drugs, TAILIN strives to build a core process development and pilot production platform that meets international GMP standards, NMPA, US FDA, EU EMA and other production quality management standards, filling China's Gaps in Cell and Gene Therapy Innovation Platforms.

Based on the advanced technology, the project will contribute to provide automatic, intelligent and cutting-edge solutions for the mass production of the biomedical industry in the future, so as to improve the efficiency of production and simplify the difficulty of factory design.